<DOC>
	<DOCNO>NCT00895245</DOCNO>
	<brief_summary>RATIONALE : Fosaprepitant dimeglumine , palonosetron hydrochloride , dexamethasone may help lessen prevent nausea vomit cause cisplatin patient head neck cancer undergo chemotherapy radiation therapy . PURPOSE : This phase II trial study well fosaprepitant dimeglumine together palonosetron hydrochloride dexamethasone work prevent nausea vomit cause cisplatin patient stage III stage IV head neck cancer undergo chemotherapy radiation therapy .</brief_summary>
	<brief_title>Fosaprepitant Dimeglumine , Palonosetron Hydrochloride , Dexamethasone Preventing Nausea Vomiting Caused Cisplatin Patients With Stage III Stage IV Head Neck Cancer Undergoing Chemotherapy Radiation Therapy</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine complete response rate anti-emetic therapy base single dose intravenous fosaprepitant multiple cycle high dose cisplatin ( complete response define emesis rescue nausea medication need 120 hour follow cisplatin infusion ) . SECONDARY OBJECTIVES : I . To determine complete response rate anti-emetic therapy base single dose intravenous fosaprepitant multiple cycle high dose cisplatin delayed period ( 25-120 hour follow cisplatin infusion ) . II . To determine efficacy anti-emetic therapy base single-dose intravenous fosaprepitant achieve adequate control nausea follow multiple cycle high-dose cisplatin define score visual analog scale &lt; 25mm 120 hour follow cisplatin infusion . III . To determine functional impact cisplatin induce nausea vomiting ( CINV ) daily life measure Functional Living Index-Emesis ( FLIE ) Questionnaire total score . OUTLINE : Patients receive cisplatin IV day 1 . Treatment repeat every 21 day 3 course . Patients also undergo 3-D conformal radiotherapy intensity-modulated radiotherapy daily 5 day week 7 week . Patients receive fosaprepitant dimeglumine IV , palonosetron hydrochloride IV , dexamethasone IV day 1 ( prior cisplatin infusion ) . Patients receive oral dexamethasone day 2-4 . Patients emesis requirement rescue anti-emetics first 120 hour cisplatin infusion continue receive anti-emetic regimen second third course cisplatin . Patients complete emesis diary ( include nausea visual analog scale ) daily 5 day cisplatin infusion . Patients also complete Functional Living Index-Emesis Questionnaire day 8 course chemotherapy .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Nausea</mesh_term>
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Laryngeal Diseases</mesh_term>
	<mesh_term>Laryngeal Neoplasms</mesh_term>
	<mesh_term>Oropharyngeal Neoplasms</mesh_term>
	<mesh_term>Nasopharyngeal Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Fosaprepitant</mesh_term>
	<mesh_term>Aprepitant</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Palonosetron</mesh_term>
	<criteria>Cytologically pathologically document squamous cell carcinoma oral cavity , oropharynx , larynx , hypopharynx , nasopharynx Stage III IV disease accord AJCC Cancer Staging Handbook Sixth Edition Planned definitive adjuvant radiation concurrent cisplatin ( 100 mg/m2 every 3 week three cycle ) ECOG Performance Status 02 Adequate Organ Function ( Hepatic : bilirubin = &lt; 1.5 x ULN ; AST ALT = &lt; 3 x ULN ; Renal : calculated creatinine clearance &gt; = 55ml/min ( use CockcroftGault Formula ) ; Bone Marrow : platelet count &gt; = 100 x 10^9/L ; absolute neutrophil count &gt; = 1.25 x 10^9/L ) Signed Informed Consent Male female patient reproductive potential must use acceptable contraceptive method ( double barrier protection premenopausal woman ) Predicted life expectancy &gt; 12 week Willingness complete patient diary questionnaire Inability unwillingness comply radiotherapy chemotherapy Use illicit drug ongoing alcohol use Vomiting within 24 hour prior cisplatin infusion Evidence clinically significant congestive heart failure ( Patients must able tolerate hydration cisplatin ) Peripheral Neuropathy &gt; Grade 2 Significant hearing loss Pregnant breastfeed woman Patients may enrol additional clinical trial , long additional investigational agent use Patients hypersensitivity fosaprepitant , aprepitant , polysorbate , component EMEND product The following therapy exclude treatment phase study : investigational agent ; antineoplastic antitumor agent , include immunotherapy , hormonal anticancer therapy ; additional schedule antiemetic medication , unless need rescue medication acute delay nausea/vomiting Strong Inhibitors CYP3A4 : ketoconazole , itraconazole , clarithromycin , ritonavir , nelfinavir ; strong Inducers CYP3A4 : rifampin , carbamazepine , phenytoin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2013</verification_date>
</DOC>